For the first time ever, Tufts CSDD has completed their initial modeling on the return on investment of decentralized clinical trials.
What did they find?
Phase II studies - Possible net benefits that are up to 5 times greater than the upfront investment required.
Phase III studies - Possible net benefits that are up to 13 times greater than the upfront investment required.
What other benefits did they find? Complete the form to receive a copy of their research.
In August 2021, Everest named Medable the leader in DCT.
